bibliographicCitation |
Kang Z, Li S, Lin Y, Li Y, Mao Y, Zhang J, Lei T, Wang H, Su Y, Yang Y, Qiu J, Li W. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. Invest New Drugs. 2023 Mar 08;41(2):296–305. doi: 10.1007/s10637-022-01325-4. |